Orexigen Therapeutics, Inc. (Nasdaq:OREX) announced that the United States Food and Drug Administration (FDA) has extended its review of the resubmitted New Drug Application (NDA) for NB32, the Company’s investigational medication being evaluated for weight loss. The newPrescription Drug User Fee Act (PDUFA) action date has been set for September 11, 2014. Orexigen Therapeutics, Inc. (NASDAQ:OREX) weekly performance is 9.49%. On last trading day company shares ended up $6.81. Analysts mean target price for the company is $11.63. Orexigen Therapeutics, Inc. (NASDAQ:OREX) distance from 50-day simple moving average (SMA50) is 18.35%.
Manufacturer of semiconductor devices Micron Technology, Inc. (NASDAQ:MU) has witnessed an insider selling his shares possibly taking advantage of the price, which is close to a yearly high price. The company’s director Lawrence Mondry has resorted to selling 10K shares on June 5 at an average price of $29.10. It has enabled him to realize the amount of $291K, as per the company’s disclosure to Securities Exchange Commission, which is a mandatory whenever a senior management executive sells shares. Micron Technology, Inc. (NASDAQ:MU) shares advanced 1.76% in last trading session and ended the day on $29.51. Gross Margin is 29.70 % and its return on assets is 15.40%. Micron Technology, Inc. (NASDAQ:MU) quarterly performance is 19.62%.
Ulta Salon, Cosmetics & Fragrance, Inc. (NASDAQ:ULTA) shares rallied in the extended session Tuesday after the cosmetics retailer topped Wall Street estimates for the quarter. Shares of Ulta rose 8.7% to $92.72 in heavy volume after the company reported first-quarter earnings of 77 cents a share on revenue of $713.8 million. Analysts had forecast earnings of 74 cents a share on revenue of $700 million. Ulta Salon, Cosmetics & Fragrance, Inc. (NASDAQ:ULTA) shares moved down -0.12% in last trading session and was closed at $85.31, while trading in range of $85.14- $87.08. Ulta Salon, Cosmetics & Fragrance, Inc. (NASDAQ:ULTA) year to date (YTD) performance is -11.61%.
OraSure Technologies Inc. (NASDAQ:OSUR) a market leader in point of care diagnostics, announced today that it has entered into a Master Program Services and Co-Promotion Agreement with AbbVie under which AbbVie and OraSure will co-promote the Company’s OraQuick(R) HCV Rapid Test in the United States. The product will be used to test individuals at-risk for hepatitis C (HCV). OraSure will be responsible for manufacturing and selling the product directly into all markets. OraSure Technologies, Inc. (NASDAQ:OSUR) ended the last trading day at $7.23. Company weekly volatility is calculated as 5.02% and price to cash ratio as 4.80. OraSure Technologies, Inc. (NASDAQ:OSUR) showed a positive weekly performance of 18.91%.
On June 9, Sirius XM Holdings Inc. (NASDAQ:SIRI)’s share trading has bagged vehement momentum off late, pumped up by the exquisite quarterly results that the company has portrayed. Sirius XM Holdings Inc. (NASDAQ:SIRI) net profit margin is 12.00% and weekly performance is 1.52%. On last trading day company shares ended up $3.35. Analysts mean target price for the company is $4.25. Sirius XM Holdings Inc. (NASDAQ:SIRI) distance from 50-day simple moving average (SMA50) is 4.49%.